CA2024196A1 - Microbilles poreuses permeables aux macromolecules comprenant au moins une substance biologique particulaire immobilisee - Google Patents
Microbilles poreuses permeables aux macromolecules comprenant au moins une substance biologique particulaire immobiliseeInfo
- Publication number
- CA2024196A1 CA2024196A1 CA 2024196 CA2024196A CA2024196A1 CA 2024196 A1 CA2024196 A1 CA 2024196A1 CA 2024196 CA2024196 CA 2024196 CA 2024196 A CA2024196 A CA 2024196A CA 2024196 A1 CA2024196 A1 CA 2024196A1
- Authority
- CA
- Canada
- Prior art keywords
- microbead
- cholesterol
- immobilized
- particulate
- microorganism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000011325 microbead Substances 0.000 title claims abstract description 88
- 229920002521 macromolecule Polymers 0.000 title claims abstract description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 157
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 74
- 244000005700 microbiome Species 0.000 claims abstract description 42
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 28
- 239000000725 suspension Substances 0.000 claims abstract description 20
- 239000011148 porous material Substances 0.000 claims abstract description 19
- 108010022197 lipoprotein cholesterol Proteins 0.000 claims abstract description 14
- 241001670040 Stenotrophomonas pictorum Species 0.000 claims abstract description 13
- 230000015556 catabolic process Effects 0.000 claims abstract description 13
- 108090000790 Enzymes Proteins 0.000 claims abstract description 12
- 102000004190 Enzymes Human genes 0.000 claims abstract description 12
- 108090001030 Lipoproteins Proteins 0.000 claims abstract description 12
- 102000004895 Lipoproteins Human genes 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 6
- 230000001580 bacterial effect Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 18
- 229920001817 Agar Polymers 0.000 claims description 17
- 239000008272 agar Substances 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 12
- 229920000936 Agarose Polymers 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 239000000679 carrageenan Substances 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000035699 permeability Effects 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- -1 antibody Proteins 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 36
- 241000894006 Bacteria Species 0.000 description 30
- 239000011324 bead Substances 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 229940072056 alginate Drugs 0.000 description 10
- 229920000615 alginic acid Polymers 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 7
- 239000000661 sodium alginate Substances 0.000 description 7
- 235000010413 sodium alginate Nutrition 0.000 description 7
- 229940005550 sodium alginate Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 239000013067 intermediate product Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- TTZLKXKJIMOHHG-UHFFFAOYSA-M benzyl-decyl-dimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 TTZLKXKJIMOHHG-UHFFFAOYSA-M 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 3
- 229920005615 natural polymer Polymers 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010093096 Immobilized Enzymes Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000008238 biochemical pathway Effects 0.000 description 2
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000777564 Penenirmus pici Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 101710100170 Unknown protein Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 235000020974 cholesterol intake Nutrition 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 244000000000 soil microbiome Species 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001248 thermal gelation Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53789990A | 1990-06-13 | 1990-06-13 | |
| US537,899 | 1990-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2024196A1 true CA2024196A1 (fr) | 1991-12-14 |
Family
ID=24144571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2024196 Abandoned CA2024196A1 (fr) | 1990-06-13 | 1990-08-29 | Microbilles poreuses permeables aux macromolecules comprenant au moins une substance biologique particulaire immobilisee |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2024196A1 (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597897A (en) * | 1991-06-21 | 1997-01-28 | Genetics Institute, Inc. | Pharmaceutical formulations of osteogenic proteins |
| US6126936A (en) * | 1995-03-10 | 2000-10-03 | Biohybrid Technologies Llc | Microcapsules and composite microreactors for immunoisolation of cells |
| WO2000065030A3 (fr) * | 1999-04-28 | 2001-01-25 | Univ Mcgill | Cellules e. coli dh5 mises au point par genie genetique, microencapsulees dans des cellules artificielles, pour l'elimination d'electrolytes et/ou de metabolites non desires |
| US6287558B1 (en) | 1997-08-01 | 2001-09-11 | Biohybrio Technologies Llc | Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule |
-
1990
- 1990-08-29 CA CA 2024196 patent/CA2024196A1/fr not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597897A (en) * | 1991-06-21 | 1997-01-28 | Genetics Institute, Inc. | Pharmaceutical formulations of osteogenic proteins |
| US6126936A (en) * | 1995-03-10 | 2000-10-03 | Biohybrid Technologies Llc | Microcapsules and composite microreactors for immunoisolation of cells |
| US6287558B1 (en) | 1997-08-01 | 2001-09-11 | Biohybrio Technologies Llc | Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule |
| WO2000065030A3 (fr) * | 1999-04-28 | 2001-01-25 | Univ Mcgill | Cellules e. coli dh5 mises au point par genie genetique, microencapsulees dans des cellules artificielles, pour l'elimination d'electrolytes et/ou de metabolites non desires |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100321665B1 (ko) | 키틴비드,키토산비드,이들비드의제조방법및이들비드로이루어지는담체및미포자충포자의제조법 | |
| JP3524096B2 (ja) | 水性媒体において膜をゲル化粒子の少なくとも表面に形成するためのエステル化多糖とポリアミンとの間のアシル交換反応の使用、それにより生成した粒子、それらの製造方法及び前記粒子を含有する組成物 | |
| US5531997A (en) | Coated transplant and method for making same | |
| US4450153A (en) | Alcohol removal from blood with alcohol oxidase | |
| JPS6188893A (ja) | 細胞により産生される物質の製造方法 | |
| JPWO1998051711A1 (ja) | キチンビーズ、キトサンビーズ、これらビーズの製造方法及びこれらビーズからなる担体並びに微胞子虫胞子の製造法 | |
| GB2094832A (en) | Process for culturing anchorage dependent cells | |
| Eichler et al. | Survival of gentamicin‐loaded carrier erythrocytes in healthy human volunteers | |
| WO1997026903A1 (fr) | Micro-organismes microencapsules issus du genie genetique pour applications cliniques | |
| Prakash et al. | In vitro and in vivo uric acid lowering by artificial cells containing microencapsulated genetically engineered E. coli DH5 cells | |
| Bramble et al. | Plant cell culture using a novel bioreactor: the magnetically stabilized fluidized bed | |
| WO1991004318A1 (fr) | Separation de cellules differentes | |
| Kampf | The use of polymers for coating of cells | |
| Murphy Jr | Effects of vitamin A on the erythrocyte membrane surface | |
| Yan et al. | A new DNA immune adsorbent for hemoperfusion in SLE therapy: a clinical trial | |
| Prakash et al. | Artificial cells microencapsulated genetically engineered E. Coli DH 5 cells for the lowering of plasma creatinine in-vitro and in-vivo | |
| Chang | [46] Methods for the therapeutic applications of immobilized enzymes | |
| Prakash et al. | Artificial cell microcapsules containing genetically engineered E. coli dhs cells for in-vitro lowering of plasma potassium, phosphate, magnesium, sodium, chloride, uric acid, cholesterol, and creatinine: a preliminary report | |
| Prakash et al. | Growth Kinetics of Genetically Engineered E. Colidh5 Cells in Artificial Cell Apa Membrane Microcapsules: Preliminary Report | |
| Garofalo et al. | Immobilization of P. Pictorijm in Open Pore Agar, Alginate and Polylysine-Alginate Microcapsules for Serum Cholesterol Depletion | |
| Prakash et al. | Artificial cells containing genetically engineered E. coli DH5 cells for urea and ammonia removal in kidney and liver failure | |
| Bernath et al. | Therapeutic perspectives of enzyme reactors | |
| SU950770A1 (ru) | Способ получени иммобилизованных протеолитических ферментов | |
| CA2243352A1 (fr) | Micro-organismes microencapsules issus du genie genetique pour applications cliniques | |
| Araki et al. | Microencapsulation of minced pancreas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |